Tag: Prescription Drugs

Rusfertide reduces number of phlebotomies and maintains hematocrit at less than 45 percent

Significant reductions seen in mean Physician Global Assessment scores and in pain, C-reactive protein, IL-6, leukocytes

Significant reduction seen in systolic blood pressure with zilebesiran 150, 300, 600 mg once in six months; 300 mg once every three months

Hydrochlorothiazide plus beta blockers recommended for patients with hypertension prior to BTKi initiation

Cefepime-taniborbactam superior for composite success, which included microbiologic and clinical success

Generally favorable effect seen in terms of number of new gadolinium-enhancing T1-weighted lesions at week 12

Percentage of patients with PASI-75 response was higher with the interleukin-23-receptor antagonist peptide

Resmetirom 80 mg and 100 mg better than placebo for patients with NASH and fibrosis stage F1B, F2, F3

Findings seen compared with glucagon-like peptide 1 receptor agonists or dipeptidyl peptidase 4 inhibitors

Greatest reduction in risk seen for those receiving 21 to 50 phosphodiesterase type 5 inhibitor prescriptions